Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: ART in Pregnancy

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in pregnancy. Topics include current recommendations and a discussion of the data to support ART options during pregnancy.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Jonah Musa, MBBS, MSCI, PhD
Released: November 8, 2021

In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic  considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.
Jonah Musa, MBBS, MSCI, PhD

Professor, Obstetrics and Gynecology
University of Jos
Honorary Consultant Obstetrician and Gynecologist
Jos University Teaching Hospital
Jos, Nigeria

Jonah Musa, MBBS, MSCI, PhD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022
Introductory Case
Question and Answer Session

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Paul E. Sax, MD Released: May 6, 2022

Expert analysis of barriers and solutions to PrEP uptake in key populations.

Joseph J. Eron, Jr., MD Gregory Huhn, MD, MPHTM Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: May 4, 2022

Slides from Dr Michelle Collins-Ogle and Clinical Care Options (CCO): There are key HIV management considerations for pediatric patients

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings